Furthermore, FOXA1 can not only serves as a predictive marker for HRD, but also harbors the potential to predict sensitivity to PARP inhibitors treatment. This evidence concerns the gene FOXA1 and hypoparathyroidism-retardation-dysmorphism syndrome.